Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Alto Neuroscience, Inc.NYSE: ANRO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $184K rose 7.6% year over year, ahead of the +5.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.6% holds above the trailing-twelve-month pace of +5.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$184K+17.2% QoQ
Last fiscal yearDec 2025
$661K+31.7% YoY
LTMMar 2026
$605K+5.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+31.7%——
3-year CAGR+24.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
661K USD
Year-over-year change
+31.7%
4-year CAGR
+46.1%

Depreciation & Amortization vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.0% is the 4th highest of 10, against a peer median of +0.0%.
  • Over three fiscal years its annual growth of +24.6% compares with a peer median of +2.4%.
ANRO Competitors
Depreciation & Amortization for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+2.9%28.9%
DBVTDBV Technologies S.A.LTM Mar 2026$12.36M USD+53.3%-27.5%—
KRROKorro Bio, Inc.LTM Mar 2026$3.44M USD-15.5%+19.5%89.4%
AMRNAmarin Corporation plcLTM Mar 2026$2.93M USD-1.6%-0.7%1.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$1.77M USD+61.3%+8.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.61M CHF-27.3%+2.0%43.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K USD+5.0%+24.6%—
SLNSilence Therapeutics plcLTM Mar 2026$577.79K USD—+4.5%62.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K USD+0.0%+3.2%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
Peer median (excluding ANRO) —+0.0%+2.4%43.6%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.